DrugPatentWatch Database Preview
Onyx Therap Company Profile
What is the competitive landscape for ONYX THERAP, and when can generic versions of ONYX THERAP drugs launch?
ONYX THERAP has one approved drug.
There are eleven US patents protecting ONYX THERAP drugs.
There are one hundred and eighty-five patent family members on ONYX THERAP drugs in forty countries and fourteen supplementary protection certificates in twelve countries.
Summary for Onyx Therap
| International Patents: | 185 |
| US Patents: | 11 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
| Patent Litigation for Onyx Therap: | See patent lawsuits for Onyx Therap |
Drugs and US Patents for Onyx Therap
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | 8,129,346 | Start Trial | Start Trial | ||||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | 8,207,127 | Start Trial | Start Trial | ||||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | 7,737,112 | Start Trial | Y | Start Trial | |||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | 9,493,582 | Start Trial | Y | Start Trial | |||
| Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-003 | Jun 7, 2018 | RX | Yes | No | Start Trial | Start Trial | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Paragraph IV (Patent) Challenges for ONYX THERAP drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | For Injection | 60 mg/vial | ➤ Subscribe | 2016-07-20 |
| ➤ Subscribe | For Injection | 10 mg/vial | ➤ Subscribe | 2018-11-28 |
International Patents for Onyx Therap Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Israel | 179151 | Start Trial |
| South Korea | 20150004797 | Start Trial |
| Cyprus | 1116771 | Start Trial |
| Israel | 221572 | Start Trial |
| Turkey | 201808563 | Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Onyx Therap Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1781688 | 16C0017 | France | Start Trial | PRODUCT NAME: CARFILZOMIB; REGISTRATION NO/DATE: EU/1/15/1060 20151123 |
| 1781688 | CA 2016 00014 | Denmark | Start Trial | PRODUCT NAME: CARFILZOMIB OG FARMACEUTISK ACCEPTABLE SALTE DERAF; REG. NO/DATE: EU/1/15/1060 20151123 |
| 1781688 | PA2016010,C1781688 | Lithuania | Start Trial | PRODUCT NAME: KARFILZOMIBAS; REGISTRATION NO/DATE: EU/1/15/1060 20151119 |
| 1781688 | C 2016 014 | Romania | Start Trial | PRODUCT NAME: CARFILZOMIB; NATIONAL AUTHORISATION NUMBER: EU/1/15/1060; DATE OF NATIONAL AUTHORISATION: 20151119; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/15/1060; DATE OF FIRST AUTHORISATION IN EEA: 20151119 |
| 1781688 | C20160008 00189 | Estonia | Start Trial | PRODUCT NAME: KARFILSOMIIB;REG NO/DATE: EU/1/15/1060 23.11.2015 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
